308 related articles for article (PubMed ID: 32150611)
21. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
22. AML evolution from preleukemia to leukemia and relapse.
Shlush LI; Mitchell A
Best Pract Res Clin Haematol; 2015; 28(2-3):81-9. PubMed ID: 26590763
[TBL] [Abstract][Full Text] [Related]
23. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia.
Paguirigan AL; Smith J; Meshinchi S; Carroll M; Maley C; Radich JP
Sci Transl Med; 2015 Apr; 7(281):281re2. PubMed ID: 25834112
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.
Short NJ; Rafei H; Daver N; Hwang H; Ning J; Jorgensen JL; Kadia TM; DiNardo CD; Wang SA; Jabbour E; Popat U; Oran B; Cortes J; Konopleva M; Yilmaz M; Issa GC; Kantarjian H; Ravandi F
Blood Adv; 2020 Dec; 4(24):6117-6126. PubMed ID: 33351107
[TBL] [Abstract][Full Text] [Related]
25. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Yilmaz M; Wang F; Loghavi S; Bueso-Ramos C; Gumbs C; Little L; Song X; Zhang J; Kadia T; Borthakur G; Jabbour E; Pemmaraju N; Short N; Garcia-Manero G; Estrov Z; Kantarjian H; Futreal A; Takahashi K; Ravandi F
Blood Cancer J; 2019 Jan; 9(2):7. PubMed ID: 30651532
[TBL] [Abstract][Full Text] [Related]
26. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments.
Simonsen AT; Meggendorfer M; Hansen MH; Nederby L; Koch S; Hansen M; Rosenberg CA; Kern W; Nyvold CG; Aggerholm A; Haferlach T; Ommen HB
Exp Hematol; 2022 Mar; 107():51-59. PubMed ID: 35122908
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
29. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
30. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser M; Heida B; Büttner K; Wienecke CP; Teich K; Funke C; Brandes M; Klement P; Liebich A; Wichmann M; Neziri B; Chaturvedi A; Kloos A; Mintzas K; Gaidzik VI; Paschka P; Bullinger L; Fiedler W; Heim A; Puppe W; Krauter J; Döhner K; Döhner H; Ganser A; Stadler M; Hambach L; Gabdoulline R; Thol F
Blood Adv; 2021 May; 5(9):2294-2304. PubMed ID: 33929500
[TBL] [Abstract][Full Text] [Related]
31. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
[TBL] [Abstract][Full Text] [Related]
32. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
33. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; Paiva B; Martínez-Cuadrón D; Bergua JM; Vives S; Algarra L; Tormo M; Martinez P; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; Gil C; Lopez JL; Vidriales MB; Labrador J; Falantes JF; Sayas MJ; Ayala R; Martinez-Lopez J; Villar S; Calasanz MJ; Prosper F; San-Miguel JF; Sanz MÁ; Montesinos P
Blood Adv; 2021 Feb; 5(3):760-770. PubMed ID: 33560390
[TBL] [Abstract][Full Text] [Related]
34. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
35. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
36. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
37. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
Itzykson R; Duployez N; Fasan A; Decool G; Marceau-Renaut A; Meggendorfer M; Jourdan E; Petit A; Lapillonne H; Micol JB; Cornillet-Lefebvre P; Ifrah N; Leverger G; Dombret H; Boissel N; Haferlach T; Preudhomme C
Blood; 2018 Jul; 132(2):187-196. PubMed ID: 29692343
[TBL] [Abstract][Full Text] [Related]
38. CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones.
Houtsma R; van der Meer NK; Meijer K; Morsink LM; Hogeling SM; Woolthuis CM; Ammatuna E; Nijk MT; de Boer B; Huls G; Mulder AB; Schuringa JJ
Blood Adv; 2022 Apr; 6(7):2129-2143. PubMed ID: 34543390
[TBL] [Abstract][Full Text] [Related]
39. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
40. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]